Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotech company specializing in RNA interference (RNAi) technology. Their mission is to target the genes that cause disease using their proprietary platform, TRiM™, to develop therapies for various medical conditions. They aim to have 20 products in clinical trials or on the market by 2025, focusing on diseases with significant unmet needs.
Industries
Nr. of Employees
large (251-1000)
Arrowhead Pharmaceuticals
Pasadena, California, United States, North America
Products
RNAi therapeutic candidate targeting APOC3 (severe hypertriglyceridemia) — clinical candidate
An RNAi therapeutic designed to reduce production of apolipoprotein C-III in liver to lower triglyceride levels; progressed into Phase 3 clinical studies with randomized, placebo-controlled designs.
RNAi therapeutic candidate targeting ANGPTL3 (mixed dyslipidemia) — clinical candidate
An RNAi therapeutic aimed at reducing production of ANGPTL3 in liver to lower LDL and triglycerides; evaluated in Phase 1 and Phase 2b randomized studies.
RNAi therapeutic candidate targeting RAGE (inflammatory pulmonary diseases) — clinical candidate
An RNAi therapeutic designed to reduce expression of the receptor for advanced glycation end-products (RAGE) as a potential treatment for inflammatory and muco-obstructive pulmonary diseases; evaluated in Phase 1/2a studies including healthy volunteers and patients.
RNAi therapeutic candidate targeting APOC3 (severe hypertriglyceridemia) — clinical candidate
An RNAi therapeutic designed to reduce production of apolipoprotein C-III in liver to lower triglyceride levels; progressed into Phase 3 clinical studies with randomized, placebo-controlled designs.
RNAi therapeutic candidate targeting ANGPTL3 (mixed dyslipidemia) — clinical candidate
An RNAi therapeutic aimed at reducing production of ANGPTL3 in liver to lower LDL and triglycerides; evaluated in Phase 1 and Phase 2b randomized studies.
RNAi therapeutic candidate targeting RAGE (inflammatory pulmonary diseases) — clinical candidate
An RNAi therapeutic designed to reduce expression of the receptor for advanced glycation end-products (RAGE) as a potential treatment for inflammatory and muco-obstructive pulmonary diseases; evaluated in Phase 1/2a studies including healthy volunteers and patients.
Services
Collaborative research partnerships
Establishing external partnerships for research and development collaborations.
Clinical development and trial sponsorship
Sponsor-side clinical trial design and execution across Phase 1–3 studies, including randomized, placebo-controlled trials and open-label extensions.
Patient access and expanded access programs
Programs and resources to support patient access to investigational therapies outside of clinical trials.
Scientific publication and data dissemination
Publication of preclinical and clinical results and dissemination of research findings.
Collaborative research partnerships
Establishing external partnerships for research and development collaborations.
Clinical development and trial sponsorship
Sponsor-side clinical trial design and execution across Phase 1–3 studies, including randomized, placebo-controlled trials and open-label extensions.
Patient access and expanded access programs
Programs and resources to support patient access to investigational therapies outside of clinical trials.
Scientific publication and data dissemination
Publication of preclinical and clinical results and dissemination of research findings.
Expertise Areas
- RNAi therapeutic development
- Clinical trial management (Phases 1–3)
- Cardiometabolic and dyslipidemia therapeutics
- Pulmonary disease therapeutics
Key Technologies
- RNA interference (RNAi)
- Targeted organ delivery platforms
- Subcutaneous drug delivery
- Pharmacokinetics / pharmacodynamics (PK/PD) assessment